Clinicopathological, epidemiological and outcome of treatment of advanced gastric cancer in Egypt: single institution experience

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Gaballah
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors A. Gaballah1, M. Moawad1, M. Yassin1, N. El-Wasly1, M. El-Mahdy2
  • 1Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, /
  • 2Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, /

Abstract

Gastric cancer is the 3rd cause of cancer related deaths worldwide. In Egypt, it is 12th in position regarding incidence and cancer-related deaths. About 65% of patients present with locally advanced or metastatic disease with 5-year survival rates of 30% and 5% respectively. Several prognostic factors had been identified for gastric cancer including stage, location, pathological subtype, peritoneal deposits, and HER2-neu over-expression. In this retrospective analysis, we are aiming at identifying the clinicopathological, epidemiological and treatment outcome for patients with advanced gastric cancer.